Key result
CMR shows no native T1 or ECV differences between asymptomatic female DMD carriers and controls.
Why the study?
Female carriers of dystrophin gene mutations were previously considered non-manifesting, but cardiomyopathy associated with muscular dystrophy and myocardial fibrosis has been described.
Does cardiovascular magnetic resonance imaging detect differences in myocardial native T1 relaxation time and extracellular volume in asymptomatic female carriers of Duchenne muscular dystrophy compared to healthy controls?
Case-Control (n=60)
No
Does cardiovascular magnetic resonance imaging detect differences in myocardial native T1 relaxation time and extracellular volume in asymptomatic female carriers of Duchenne muscular dystrophy compared to healthy controls?
Absolute Event Rate: 1005.1% vs 1003.5%
p-value: p=0.81
In asymptomatic female carriers of Duchenne muscular dystrophy, CMR-derived native T1 mapping and ECV quantification did not show significant global or segmental myocardial fibrosis compared to healthy controls.
No takes yet. Share an insight, caveat, or question.
CMR T1 mapping and ECV do not detect myocardial differences in asymptomatic DMD carriers; leaves open need for longitudinal or segmental assessment.
Masárová et al. (2023) conducted a case-control in Asymptomatic female carriers of Duchenne muscular dystrophy gene mutations (n=60). Cardiovascular magnetic resonance (CMR) imaging vs. Healthy volunteers was evaluated on Mean global native T1 relaxation time (p=0.81). Cardiovascular magnetic resonance imaging showed no statistically significant differences in mean global native T1 relaxation time (1005.1 vs. 1003.5 ms) or extracellular volume (27.92% vs. 27.10%) between asymptomatic female carriers of Duchenne muscular dystrophy and healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: